Radiotherapy and Immunogenic Cell Death

Seminars in Radiation Oncology

Volumn 25, Issue 1, 2015, Pages 11-17

  Golden, Encouse B ^a   Apetoh, Lionel ^b,c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Institut Médical de Génétique et d Immunologie   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PURINERGIC P2X RECEPTOR; PURINERGIC P2X RECEPTOR 7; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL DEATH; HUMAN; IMMUNOGENIC CELL DEATH; INTESTINE FLORA; LUNG CANCER; LYMPHOMA; MELANOMA; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; REVIEW; WHOLE BODY RADIATION; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; RADIATION RESPONSE;

CELL DEATH; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 84919464054     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2014.07.005     Document Type: Review

References (50)

1. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10(7):718-726.
2. Golden E.B., Formenti S.C. Is tumor (r)ejection by the immune system the "5th R" of radiobiology. Oncoimmunology 2014, 3(1):e28133.
3. Postow M.A., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366(10):925-931.
4. Golden E.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1(6):365-372.
5. Demaria S., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58(3):862-870.
6. Demaria S., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11(2 Pt 1):728-734.
7. Dewan M.Z., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15(17):5379-5388.
8. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 2013, 105(4):256-265.
9. Ma Y., et al. Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Semin Immunol 2010, 22(3):113-124.
10. Chakravarty P.K., et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999, 59(24):6028-6032.
11. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13(9):1050-1059.
12. Ghiringhelli F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15(10):1170-1178.
13. Formenti S.C., Demaria S. Local control by radiotherapy: Is that all there is?. Breast Cancer Res 2008, 10(6):215.
14. Golden E.B., Frances D., Pellicciotta I., Demaria S., Helen Barcellos-Hoff M., Formenti S.C. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014, 3:e28518.
15. Panaretakis T., et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009, 28(5):578-590.
16. Obeid M., et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007, 14(10):1848-1850.
17. Perez C.A., et al. Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol 2009, 85(12):1126-1136.
18. Willingham S.B., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012, 109(17):6662-6667.
19. Khandelwal S., van Rooijen N., Saxena R.K. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 2007, 47(9):1725-1732.
20. Maxhimer J.B., et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 2009, 1(3):3ra7.
21. Vermeer D.W., et al. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer 2013, 133(1):120-129.
22. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5(4):331-342.
23. Michaud M., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334(6062):1573-1577.
24. Zappasodi R., et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010, 70(22):9062-9072.
25. Ohshima Y., et al. gamma-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta 2010, 1800(1):40-46.
26. Petrovski G., et al. Phagocytosis of cells dying through autophagy induces inflammasome activation and IL-1beta release in human macrophages. Autophagy 2011, 7(3):321-330.
27. Reits E.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203(5):1259-1271.
28. Ruocco M.G., et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest 2012, 122(10):3718-3730.
29. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336(6086):1268-1273.
30. Viaud S., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342(6161):971-976.
31. Martin F., Apetoh L., Ghiringhelli F. Controversies on the role of Th17 in cancer: A TGF-beta-dependent immunosuppressive activity?. Trends Mol Med 2012, 18(12):742-749.
32. Meyer C., et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014, 63(3):247-257.
33. Robin H.I., et al. The abscopal effect: Demonstration in lymphomatous involvement of kidneys. Med Pediatr Oncol 1981, 9(5):473-476.
34. Wersall P.J., et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 2006, 45(4):493-497.
35. Stamell E.F., et al. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013, 85(2):293-295.
36. Sullivan R.J., et al. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med 2013, 369(2):173-183.
37. Demaria S., et al. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology 2013, 2(10):e25997.
38. Adams S., et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 2012, 18(24):6748-6757.
39. Dewan M.Z., et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res 2012, 18(24):6668-6678.
40. Brody J.D., et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J Clin Oncol 2010, 28(28):4324-4332.
41. Barker C.A., Postow M.A. Combinations of radiation therapy and immunotherapy for melanoma: A review of clinical outcomes. Int J Radiat Oncol Biol Phys 2014, 88(5):986-997.
42. Russell J.S., Brown J.M. The irradiated tumor microenvironment: Role of tumor-associated macrophages in vascular recovery. Front Physiol 2013, 4:157.
43. Golden E.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 10.1158/2326-6066.CIR-13-0115.
44. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: A magic bullet?. Science 2013, 339(6117):286-291.
45. Klug F., et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013, 24(5):589-602.
46. Glynne-Jones R., Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: A flawed paradigm?. J Clin Oncol 2007, 25(33):5281-5286.
47. Formenti S.C., Demaria S. Effects of chemoradiation on tumor-host interactions: The immunologic side. J Clin Oncol 2008, 26(9):1562-1563. [author reply 1563].
48. Bruchard M., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013, 19(1):57-64.
49. Huh J.R., Littman D.R. Small molecule inhibitors of RORgammat: Targeting Th17 cells and other applications. Eur J Immunol 2012, 42(9):2232-2237.
50. Dudley M.E., et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26(32):5233-5239.